{"DataElement":{"publicId":"3438590","version":"1","preferredName":"Histologic Response Post Neoadjuvant Therapy Necrosis Percent Value","preferredDefinition":"Numeric value to represent the histological response to neoadjuvant therapy as measured by percentage of cell death within the tumor.","longName":"3437714v1.0:2180234v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3437714","version":"1","preferredName":"Histologic Response Post Neoadjuvant Therapy","preferredDefinition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._Happening at a time subsequent to a reference time; later in time or order._Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.","longName":"3437711v1.0:3437712v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3437711","version":"1","preferredName":"Histologic Response","preferredDefinition":"Of or relating to histology.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C25526:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Histologic","conceptCode":"C25526","definition":"Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF39C31-3EE7-61BC-E040-BB89AD43570A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3437712","version":"1","preferredName":"Post Neoadjuvant Therapy","preferredDefinition":"Happening at a time subsequent to a reference time; later in time or order.:Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains.","longName":"C38008:C15665","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post","conceptCode":"C38008","definition":"Happening at a time subsequent to a reference time; later in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF39C31-3EF5-61BC-E040-BB89AD43570A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-18","modifiedBy":"ONEDATA","dateModified":"2012-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF39C31-3F06-61BC-E040-BB89AD43570A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for TARGET per request by T.Davidsen and approved for release by D.Barkauskas. mc 4/24/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2180234","version":"1","preferredName":"Lab Percentage Value","preferredDefinition":"the value as a percentage of 100.","longName":"LAB_PTG_VAL","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208119","version":"1","preferredName":"Percentage Value","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator.:A numerical quantity measured or assigned or computed.","longName":"C25613:C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3E46-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D173674B-2AF0-17B7-E034-0003BA12F5E7","latestVersionIndicator":"No","beginDate":"2004-01-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-21","modifiedBy":"CAMPBELB","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5650570","version":"1","longName":"TARGET","context":"OCG","ClassificationSchemeItems":[{"publicId":"5650574","version":"1","longName":"NBL","context":"OCG"},{"publicId":"5650575","version":"1","longName":"OS","context":"OCG"}]},{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"5806869","version":"1","longName":"Pediatric Osteosarcoma","context":"OCG"},{"publicId":"5946223","version":"1","longName":"Ewing's Sarcoma","context":"OCG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"PctNcr","type":"COG GDE Short Name","context":"COG"},{"name":"OCG","type":"USED_BY","context":"OCG"},{"name":"percent_necrosis","type":"HCMI Name","context":"OCG"},{"name":"sarcoma_tumor_total_necrosis","type":"HCMI Name","context":"OCG"},{"name":"Theradex","type":"USED_BY","context":"Theradex"}],"ReferenceDocuments":[{"name":"Percent necrosis","type":"Preferred Question Text","description":"Percent necrosis","url":null,"context":"NCIP"},{"name":"TARGET Question","type":"Alternate Question Text","description":"Percent necrosis at definitive surgery","url":null,"context":"NCIP"},{"name":"HCMI Question Text","type":"Alternate Question Text","description":"Percent tumor necrosis (at resection, primary tumor)","url":null,"context":"OCG"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"% Tumor Necrosis","url":null,"context":"Theradex"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BDF86B4A-3D82-584B-E040-BB89AD43471A","latestVersionIndicator":"Yes","beginDate":"2012-04-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-18","modifiedBy":"SOKKERL","dateModified":"2017-11-30","changeDescription":"Created for TARGET per request by T.Davidsen and approved for release by D.Barkauskas. mc 4/24/12 Added alt question text for TARGET update per request by Tanja. mc 12/23/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}